Summary of the Risk Management Plan

Summary of Risk Management Plan for Lonquex (lipegfilgrastim)

This is a summary of the risk management plan (RMP) for Lonquex (lipegfilgrastim) (herein after also referred to as lipegfilgrastim). The RMP details important risks of lipegfilgrastim, and how more information will be obtained about lipegfilgrastim´s risks and uncertainties (missing information).

Lipegfilgrastim´s summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how lipegfilgrastim should be used.

This summary of the RMP for lipegfilgrastim should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of lipegfilgrastim´s RMP.

I. The Medicine and What It is used for

Lonquex (lipegfilgrastim) is authorised in adults and in children 2years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) (see SmPC for the full indication). It contains lipegfilgrastim as the active substance and it is given by subcutaneous injection.

Further information about the evaluation of Lonquex's benefits can be found in Lonquex's EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex.

II. Risks Associated with the Medicine and Activities to Minimise or Further Characterise the Risks

Important risks of lipegfilgrastim, together with measures to minimise such risks and the proposed studies for learning more about lipegfilgrastim´s risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of Important Risks and Missing Information

Important risks of Lonquex are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Lonquex. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Table 1: Summary of Safety Concerns

List of important risks and missing information	
Important identified risks	*None*
Important potential risks	*None*
Missing information	*None*

II.B Summary of Important Risks

Not applicable.

II.C Post-Authorisation Development Plan

II.C.1 Studies Which Are Conditions of the Marketing Authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Lipegfilgrastim.

II.C.2 Other Studies in Post-Authorisation Development Plan

There are no studies required for Lipegfilgrastim.